首页> 外文学位 >The effect of HIV protease inhibitors on insulin binding, triglyceride synthesis, lipolysis, and insulin signaling in 3T3-L1 adipocytes (Immune deficiency).
【24h】

The effect of HIV protease inhibitors on insulin binding, triglyceride synthesis, lipolysis, and insulin signaling in 3T3-L1 adipocytes (Immune deficiency).

机译:HIV蛋白酶抑制剂对3T3-L1脂肪细胞中的胰岛素结合,甘油三酸酯合成,脂解作用和胰岛素信号传导的影响(免疫缺陷)。

获取原文
获取原文并翻译 | 示例

摘要

Retroviral protease inhibitors used as therapy for HIV-infection have been causally associated with serious metabolic side effects, including peripheral lipodystrophy, central adiposity, hyperlipidaemia, insulin resistance, and in some cases, type 2 diabetes. The etiology of this characteristic clinical syndrome remains unknown.; We demonstrate that the HIV protease inhibitors (PIs), saquinavir, indinavir, and ritonavir inhibit adipocyte differentiation of 3T3-L1 preadipocytes. Furthermore, they exert a dose-dependent increase in basal triacylglycerol synthesis followed by a concomitant decrease in insulin-stimulated triacylglycerol synthesis. However, PIs did not stimulate lipolysis under basal or norepinephrine-stimulated conditions in mature 3T3-L1 adipocytes. Also, this study reports an inhibition of specific 125I-Insulin binding to insulin receptors in the presence of PIs throughout distinct stages of 3T3-L1 adipocyte differentiation. Additionally, this inhibition was found to be reversable upon removal of the PIs during the binding process. However, insulin binding affinities and processing were not affected by PIs.; To continue, we investigated whether the HIV protease inhibitor ritonavir altered insulin signaling. In cells not exposed to ritonavir, insulin led to a rapid increase of insulin-receptor substrate-1-phosphorylation. In ritonavir-treated cells, these insulin stimulated increases were reduced by approximately 50%.; We conclude that HIV protease inhibitors are capable of selectively inhibiting the insulin response and contributing to the metabolic abnormalities seen in HIV-infected patients.
机译:逆转录病毒蛋白酶抑制剂被用作HIV感染的治疗剂,与严重的代谢副作用有因果关系,包括周围的脂肪营养不良,中枢性肥胖,高脂血症,胰岛素抵抗,在某些情况下还包括2型糖尿病。该特征性临床综合征的病因仍未知。我们证明,HIV蛋白酶抑制剂(PIs),沙奎那韦,茚地那韦和利托那韦抑制3T3-L1前脂肪细胞的脂肪细胞分化。此外,它们在基础三酰甘油合成中具有剂量依赖性的增加,随后伴随胰岛素刺激的三酰甘油合成的降低。但是,在成熟的3T3-L1脂肪细胞中,在基础或去甲肾上腺素刺激的条件下,PI不会刺激脂解。同样,该研究报告了在3T3-L1脂肪细胞分化的不同阶段中,在PI的存在下,特定的 125 I-胰岛素与胰岛素受体的结合受到抑制。另外,发现在结合过程中去除PI后该抑制作用是可逆的。但是,胰岛素结合亲和力和加工不受PI影响。接下来,我们调查了HIV蛋白酶抑制剂利托那韦是否改变了胰岛素信号传导。在未暴露于利托那韦的细胞中,胰岛素导致胰岛素受体底物-1-磷酸化迅速增加。在利托那韦处理的细胞中,这些胰岛素刺激的增加减少了约50%。我们得出的结论是,HIV蛋白酶抑制剂能够选择性抑制胰岛素反应,并有助于在HIV感染患者中看到代谢异常。

著录项

  • 作者

    Cammalleri, Caterina.;

  • 作者单位

    Concordia University (Canada).;

  • 授予单位 Concordia University (Canada).;
  • 学科 Biology Cell.
  • 学位 M.Sc.
  • 年度 2002
  • 页码 132 p.
  • 总页数 132
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 细胞生物学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号